Enjoy complimentary customisation on priority with our Enterprise License!
Hemophilia B, commonly known as Christmas disease, is a genetic blood coagulation disorder that is caused due to factor IX deficiency. Even though this is an inherited disease, approximately one-third of the cases occur due to spontaneous gene mutation. Analysts estimate the market for hemophilia B to surpass US$ 2 billion due to the advent of plasma-derived and recombinant factor replacement therapeutics.
Technavio’s market research analysts estimate the Americas to account for approximately 44% of the total market revenue during the forecast period. This region’s domination of the market can be attributed to the increase in prophylactic treatment and development of long-acting hemophilia B therapeutic products.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.